Crucial roles of GATA-2 and SP1 in adrenomedullin-affected expression of tissue factor pathway inhibitor in human umbilical vein endothelial cells exposed to lipopolysaccharide

Summary

Adrenomedullin (ADM) is a vasodilator peptide that has a variety of effects, including antithrombotic activities and resistant roles to lipopolysaccharide (LPS)-induced septic shock. During sepsis,LPS triggers the development of disseminated intravascular coagulation (DIC) via the tissue factor-dependent pathway of coagulation.It is unknown whether the antithrombotic activities of ADM contribute to its resistance to sepsis. In the present study, we investigated the effects of ADM on tissue factor pathway inhibitor (TFPI) (primary anticoagulant factor) expression in human umbilical vein endothelial cells (HUVECs) exposed to LPS,and the possible underlying mechanism for these effects.Exposure of HUVECs to LPS for 12 hours caused significant decrease of TFPI protein activities and mRNA expression.These effects were abolished by treatment withADM (10^–10 to 10^–6 M), cAMP analogue and calcium antagonist. Accordingly, cAMP antagonist inhibited the counteraction effect of ADM on LPS in TFPI expression. Electrophoresis mobility shift assay (EMSA) and Western blot analysis showed that the protein level of GATA-2 and SP1 transcriptional factors and their binding to the corresponding regulatory sequences decreased by LPS treatment. And these effects of LPS were antagonized by ADM. Promoter- reporter assays and mutational analysis also confirmed the roles of GATA-2 and SP1 motifs from –1247 to –381bp promoter sequence in TFPI inducible expression. Taken together, these results indicate that ADM antagonizes the effect of LPS on TFPI expression, which is mediated by affecting transcriptional factor GATA-2 and SP1 through cAMP and calcium signaling pathway.

Keywords

Adrenomedullin - human umbilical vein endothelial cells - tissue factor pathway inhibitor - transcriptional factor

^* These authors contributed to this work equally.

• References

• 1 Lee YM. et al. Scoparone inhibits tissue factor expression in lipopolysaccharide-activated human umbilical vein endothelial cells. J Biomed Sci 2003; 10: 518-525.
• 2 Molor-Erdene P. et al. Inhibition of lipopolysaccharide- induced tissue factor expression in monocytes by urinary trypsin inhibitor in vitro and in vivo. Thromb Haemost 2005; 94: 136-145.
• 3 Hara S. et al. Expression of tissue factor and tissue factor pathway inhibitor in rats lungs with lipopolysaccharide- induced disseminated intravascular coagulation. Lab Invest 1997; 77: 581-589.
• 4 de Waard V. et al. Differential expression of tissue factor mRNA and protein expression in murine sepsis. The role of the granulocyte revisited. Thromb Haemost 2006; 95: 348-353.
• 5 Mackman N. et al. Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol 1993; 143: 76-84.
• 6 Erlich J. et al. Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun 1999; 67: 2540-2546.
• 7 Bajaj MS. et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-8873.
• 8 Shimokawa T. et al. Down-regulation of murine tissue factor pathway inhibitor mRNA by endotoxin and tumor necrosis factor-alpha in vitro and in vivo. Thromb Res 2000; 100: 211-221.
• 9 de Jonge E. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.
• 10 Opal SM. et al. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 2001; 29: 13-17.
• 11 Kitamura K. et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
• 12 Eto T. et al. Biological and clinical roles of adrenomedullin in circulation control and cardiovascular diseases. Clin Exp Pharmacol Physiol 1999; 26: 371-380.
• 13 Cheung BM. et al. Increased adrenomedullin expression in lungs in endotoxaemia. J Endocrinol 2004; 181: 339-345.
• 14 Nishio K. et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med 1997; 25: 953-957.
• 15 Wang P. Adrenomedullin in sepsis and septic shock. Shock 1998; 10: 383-384.
• 16 Matsui E. et al. Biosynthesis and secretion of adrenomedullin and proadrenomedullin N-terminal 20 peptide in a rat model of endotoxin shock. Hypertens Res 2001; 24: 543-549.
• 17 Shoji H. et al. Endotoxin markedly elevates plasma concentration and gene transcription of adrenomedullin in rat. Biochem Biophys Res Commun 1995; 215: 531-537.
• 18 Agorreta J. et al. Adrenomedullin expression in a rat model of acute lung injury induced by hypoxia and LPS. Am J Physiol Lung Cell Mol Physiol 2005; 288: L536-545.
• 19 Shindo T. et al. Upregulation of endothelin-1 and adrenomedullin gene expression in the mouse endotoxin shock model. J Cardiovasc Pharmacol 1998; 31 (Suppl. 01) (Suppl) S541-544.
• 20 Li YY. et al. Adrenomedullin gene expression and levels in the cardiovascular system after treatment with lipopolysaccharide. Neuropeptides 2005; 39: 73-80.
• 21 Tomoda Y. et al. Regulation of adrenomedullin secretion from cultured cells. Peptides 2001; 22: 1783-1794.
• 22 Shindo T. et al. Hypotension and resistance to lipopolysaccharide- induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. Circulation 2000; 101: 2309-2316.
• 23 Imai Y. et al. Evidence for the physiological and pathological roles of adrenomedullin from genetic engineering in mice. Ann NY Acad Sci 2001; 947: 26-34.
• 24 Sugano T. et al. Adrenomedullin inhibits angiotensin II-induced expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1078-1083.
• 25 Marutsuka K. et al. Adrenomedullin augments the release and production of tissue factor pathway inhibitor in human aortic endothelial cells. Cardiovasc Res 2003; 57: 232-237.
• 26 Jaffe EA. et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. Clin Invest 1973; 52: 2745-2756.
• 27 Simpson P. et al. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 1982; 51: 787-801.
• 28 Grynkiewicz G. et al. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450.
• 29 Chiu JJ. et al. Shear stress attenuates tumor necrosis factor- α -induced monocyte chemotactic protein-1 expressions in endothelial cells. Chin J Physiol 2002; 45: 169-176.
• 30 Petit L. et al. The promoter of human tissue factor pathway inhibitor gene: identification of potential regulatory elements. Thromb Res 1999; 95: 255-262.
• 31 Michibata H. et al. Autocrine/paracrine role of adrenomedullin in cultured endothelial and mesangial cells. Kidney Int 1998; 53: 979-985.
• 32 Tyson DR. et al. Revised DNA sequence of exon 1 and 5' flanking region of the human tissue factor pathway inhibitor gene. Thromb Res 1993; 70: 269-273.
• 33 Hamilton G. et al. Endotoxin, TNF-alpha, interleukin- 6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis 1992; 24: 361-368.
• 34 Wada Y. et al. Preconditioning of primary human endothelial cells with inflammatory mediators alters the "set point" of the cell. FASEB J 2005; 19: 1914-1916.
• 35 Vignoli A. et al. Differential effect of the low-molecular- weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 2006; 91: 207-214.
• 36 Lee YM. et al. Scoparone inhibits tissue factor expression in lipopolysaccharide-activated human umbilical vein endothelial cells. J Biomed Sci 2003; 10: 518-525.
• 37 Johnson K. et al. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87: 5051-5060.
• 38 Bucki R, Pastore JJ. Bacterial endotoxin as inhibitor of the enzymatic activity of human thrombin. Eur J Haematol 2006; 76: 510-515.
• 39 Kano H. et al. Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. J Hypertens 1996; 14: 209-213.
• 40 Hinson JP. et al. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000; 21: 138-167.
• 41 Mazzocchi G. et al. Adrenomedullin and calcitonin gene-related peptide inhibit aldosterone secretion in rats, acting via a common receptor. Life Sci 1996; 58: 839-844.
• 42 Dannenberg LO. et al. GATA-2 and HNF-3beta regulate the human alcohol dehydrogenase 1A (ADH1A) gene. DNA Cell Biol 2005; 24: 543-552.
• 43 Brecht K. et al. Hematopoietic transcription factor GATA-2 promotes upregulation of alpha globin and cell death in FL5.12 cells. Apoptosis 2005; 10: 1063-1078.
• 44 Minami T. et al. Interaction between hex and GATA transcription factors in vascular endothelial cells inhibits flk-1/KDR-mediated vascular endothelial growth factor signaling. J Biol Chem 2004; 279: 20626-20635.
• 45 Lee ME. et al. Cloning of the GATA-binding protein that regulates endothelin-1 gene expression in endothelial cells. J Biol Chem 1991; 266: 16188-16192.
• 46 Dorfman DM. et al. Human transcription factor GATA-2. Evidence for regulation of preproendothelin- 1 gene expression in endothelial cells. J Biol Chem 1992; 267: 1279-1285.
• 47 Bajaj MS. et al. Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignant cells. Thromb Res 2001; 101: 203-211.
• 48 Chen YQ. et al. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998; 273: 8225-8231.
• 49 Tanaka T. et al. Inducible expression of manganese superoxide dismutase by phorbol 12-myristate 13-acetate is mediated by Sp1 in endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 392-401.